PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
De Santana Villasboas Arruda, A.L. ; Khandaker, G.M.* ; Morris, A.P.* ; Smith, G.D.* ; Huckins, L.M.* ; Zeggini, E.

Genomic insights into the comorbidity between type 2 diabetes and schizophrenia.

Schizophr. 10:22 (2024)
Verlagsversion DOI PMC
Free journal
Creative Commons Lizenzvertrag
Multimorbidity represents an increasingly important public health challenge with far-reaching implications for health management and policy. Mental health and metabolic diseases have a well-established epidemiological association. In this study, we investigate the genetic intersection between type 2 diabetes and schizophrenia. We use Mendelian randomization to examine potential causal relationships between the two conditions and related endophenotypes. We report no compelling evidence that type 2 diabetes genetic liability potentially causally influences schizophrenia risk and vice versa. Our findings show that increased body mass index (BMI) has a protective effect against schizophrenia, in contrast to the well-known risk-increasing effect of BMI on type 2 diabetes risk. We identify evidence of colocalization of association signals for these two conditions at 11 genomic loci, six of which have opposing directions of effect for type 2 diabetes and schizophrenia. To elucidate these colocalizing signals, we integrate multi-omics data from bulk and single-cell gene expression studies, along with functional information. We identify putative effector genes and find that they are enriched for homeostasis and lipid-related pathways. We also highlight drug repurposing opportunities including N-methyl-D-aspartate (NMDA) receptor antagonists. Our findings provide insights into shared biological mechanisms for type 2 diabetes and schizophrenia, highlighting common factors that influence the risk of the two conditions in opposite directions and shedding light on the complex nature of this comorbidity.
Impact Factor
Scopus SNIP
Altmetric
3.000
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Nogo-b Receptor; R Package; Risk; Association; Expression; Digoxin; Brain; Mechanisms; Regression; Disorders
Sprache englisch
Veröffentlichungsjahr 2024
HGF-Berichtsjahr 2024
ISSN (print) / ISBN 2754-6993
e-ISSN 2754-6993
Zeitschrift Schizophrenia
Quellenangaben Band: 10, Heft: 1, Seiten: , Artikelnummer: 22 Supplement: ,
Verlag Nature Publishing Group
Verlagsort Heidelberger Platz 3, Berlin, 14197, Germany
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Translational Genomics (ITG)
POF Topic(s) 30205 - Bioengineering and Digital Health
Forschungsfeld(er) Genetics and Epidemiology
Enabling and Novel Technologies
PSP-Element(e) G-506700-001
G-506701-001
Förderungen NIEHS
NCI
NHGRI
NHLBI
NIDA
NIMH
NINDS - Medical Research Council (MRC)
University of Bristol
Wellcome Trust
UK Medical Research Council
UK National Institute of Health Research Bristol Biomedical Research Centre
National Institutes of Health: NIMH
Common Fund of the Office of the Director of the National Institutes of Health
DOI 10.1038/s41537-024-00445-5
WOS ID 001228610600001
Scopus ID 85185666348
PubMed ID 38383672
Erfassungsdatum 2024-04-25
[➜Korrektur melden]